» Articles » PMID: 39209475

Definition, Classification and Diagnosis of Pulmonary Hypertension

Overview
Journal Eur Respir J
Specialty Pulmonary Medicine
Date 2024 Aug 29
PMID 39209475
Authors
Affiliations
Soon will be listed here.
Abstract

Pulmonary hypertension (PH) is a haemodynamic condition characterised by elevation of mean pulmonary arterial pressure (mPAP) >20 mmHg, assessed by right heart catheterisation. Pulmonary arterial wedge pressure (PAWP) and pulmonary vascular resistance (PVR) distinguish pre-capillary PH (PAWP ≤15 mmHg, PVR >2 Wood Units (WU)), isolated post-capillary PH (PAWP >15 mmHg, PVR ≤2 WU) and combined post- and pre-capillary PH (PAWP >15 mmHg, PVR >2 WU). Exercise PH is a haemodynamic condition describing a normal mPAP at rest with an abnormal increase of mPAP during exercise, defined as a mPAP/cardiac output slope >3 mmHg/L/min between rest and exercise. The core structure of the clinical classification of PH has been retained, including the five major groups. However, some changes are presented herewith, such as the re-introduction of "long-term responders to calcium channel blockers" as a subgroup of idiopathic pulmonary arterial hypertension, the addition of subgroups in group 2 PH and the differentiation of group 3 PH subgroups based on pulmonary diseases instead of functional abnormalities. Mitomycin-C and carfilzomib have been added to the list of drugs with "definite association" with PAH. For diagnosis of PH, we propose a stepwise approach with the main aim of discerning those patients who need to be referred to a PH centre and who should undergo invasive haemodynamic assessment. In case of high probability of severe pulmonary vascular disease, especially if there are signs of right heart failure, a fast-track referral to a PH centre is recommended at any point during the clinical workup.

Citing Articles

The role of lactate metabolism and lactylation in pulmonary arterial hypertension.

Peng T, Lu J, Zheng X, Zeng C, He Y Respir Res. 2025; 26(1):99.

PMID: 40075458 PMC: 11905457. DOI: 10.1186/s12931-025-03163-3.


Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox.

Pulido T, de la Cruz-Perez S, Valencia D, Conde R, Lescano A, Zayas N Int J Cardiol Congenit Heart Dis. 2025; 19:100573.

PMID: 40066342 PMC: 11891735. DOI: 10.1016/j.ijcchd.2025.100573.


Sleep apnea in pulmonary hypertension patients: a systematic review and meta-analysis sleep disorders and pulmonary hypertension.

Akbari A, Raji H, Islampanah M, Barati S, Davoodian N, Aminizadeh S Sleep Breath. 2025; 29(1):120.

PMID: 40056328 DOI: 10.1007/s11325-025-03280-9.


Unveiling the threat of crystalline silica on the cardiovascular system. A comprehensive review of the current knowledge.

Gurzu I, Handra C, Ghita I, Otelea M Front Cardiovasc Med. 2025; 12:1506846.

PMID: 40027509 PMC: 11868085. DOI: 10.3389/fcvm.2025.1506846.


Treatment Approaches for Pulmonary Hypertension in Colombia: A Call to Action.

Pitsiou G Clin Respir J. 2025; 19(2):e70062.

PMID: 39949156 PMC: 11825980. DOI: 10.1111/crj.70062.


References
1.
Lechartier B, Boucly A, Solinas S, Gopalan D, Dorfmuller P, Radonic T . Pulmonary veno-occlusive disease: illustrative cases and literature review. Eur Respir Rev. 2024; 33(171). PMC: 10792437. DOI: 10.1183/16000617.0156-2023. View

2.
Eichstaedt C, Belge C, Chung W, Graf S, Grunig E, Montani D . Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH. Eur Respir J. 2022; 61(2). PMC: 9947314. DOI: 10.1183/13993003.01471-2022. View

3.
Zeder K, Banfi C, Steinrisser-Allex G, Maron B, Humbert M, Lewis G . Diagnostic, prognostic and differential-diagnostic relevance of pulmonary haemodynamic parameters during exercise: a systematic review. Eur Respir J. 2022; 60(4). PMC: 9556812. DOI: 10.1183/13993003.03181-2021. View

4.
Kovacs G, Avian A, Olschewski A, Olschewski H . Zero reference level for right heart catheterisation. Eur Respir J. 2013; 42(6):1586-94. DOI: 10.1183/09031936.00050713. View

5.
Le Pavec J, Valeyre D, Gazengel P, Holm A, Schultz H, Perch M . Lung transplantation for sarcoidosis: outcome and prognostic factors. Eur Respir J. 2021; 58(2). DOI: 10.1183/13993003.03358-2020. View